UCB SA (OTCMKTS:UCBJF – Get Free Report) reached a new 52-week high on Thursday . The company traded as high as $200.00 and last traded at $200.00, with a volume of 35 shares trading hands. The stock had previously closed at $197.03.
UCB Stock Performance
The stock has a 50-day simple moving average of $184.31 and a two-hundred day simple moving average of $170.03. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Dividend Payout Ratio Calculator
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- What is the Euro STOXX 50 Index?
- Nebius Group: The Rising Star in AI Infrastructure
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
